Public Funding Essential for Advances in Biomedical Research

In the budget President Trump recently submitted to Congress, he asked for a reduction in the 2018 funding of the U.S. National Institutes of Health (NIH) of almost 20 percent - or $6 billion. That could have consequences for those suffering from a variety of illnesses and conditions and for biomedical innovation, based on results from an article to be published in Science and coauthored by Assistant Professor Danielle Li of Harvard Business School, Professor Pierre Azoulay of MIT Sloan School of Management and the National Bureau of Economic Research (NBER), and Associate Professor Bhaven N. Sampat of Columbia University's Mailman School of Public Health and NBER.

"Our article, 'The Applied Value of Public Investments in Biomedical Research,' shows that publicly-funded research creates knowledge that links to private companies' efforts to develop drugs, medical devices, and other patented biomedical products," says Harvard's Li. "We find that 30 percent of NIH-funded grants produce research that is cited by a private-sector patent."

NIH, the world's largest single funder of research in the life sciences, provides support for one-third of biomedical R&D in the United States, as well as the majority of funding for so-called "basic" or broad-based biomedical research. Using data on life science patents (including drugs, devices, and other medical technologies), Li, Azoulay, and Sampat analyze the output of research grants awarded by NIH over a 27-year period and provide a method for large-scale accounting of linkages between these public research investments and their commercial applications. Recognizing that some patents are more valuable than others, they also examine linkages between NIH grants and patents associated with marketed drugs.

"We find that about 10 percent of NIH grants generate a patent directly - an easier-to-grasp metric that policy makers often focus on to capture the near-term economic returns to public funding of biomedical R&D," say the authors. "According to our research, however, a much larger number of NIH grants - about 30 percent of them - generate articles that are subsequently cited by commercial patents. Focusing solely on the direct patent output of NIH funding may dramatically understate its importance for producing research that informs commercial innovation."

In addition, Li, Azoulay, and Sampat find that grants for "basic" science are almost just as likely to be cited by patents as grants for more "applied" work - which may be surprising to those who question its practical value.

Danielle Li, Pierre Azoulay, Bhaven N. Sampat.
The applied value of public investments in biomedical research.
Science, 2017, eaal0010, doi: 10.1126/science.aal0010.

Most Popular Now

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

New AI Transforms Radiology with Speed, …

A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology - boosting productivity, identifying life-threatening conditions in milliseconds and offering a breakthrough solution to the global radiologist...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

New Research Finds Specific Learning Str…

If data used to train artificial intelligence models for medical applications, such as hospitals across the Greater Toronto Area, differs from the real-world data, it could lead to patient harm...

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

Patients say "Yes..ish" to the…

As artificial intelligence (AI) continues to be integrated in healthcare, a new multinational study involving Aarhus University sheds light on how dental patients really feel about its growing role in...

'AI Scientist' Suggests Combin…

An 'AI scientist', working in collaboration with human scientists, has found that combinations of cheap and safe drugs - used to treat conditions such as high cholesterol and alcohol dependence...

Brains vs. Bytes: Study Compares Diagnos…

A University of Maine study compared how well artificial intelligence (AI) models and human clinicians handled complex or sensitive medical cases. The study published in the Journal of Health Organization...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...